All Oncology News

Diane Simeone, MD, discusses recent data on neoadjuvant and adjuvant therapy for patients with locally advanced or resectable pancreatic cancer, and questions surrounding germline testing for earlier identification of this disease.

Oncology practices that are participating in the Centers for Medicare & Medicaid Innovation’s Oncology Care Model are willing to take on two-sided risk with value-based care and shift from a fee-for-service approach.

Treatment with a CD19-targeted CAR-natural killer–cell therapy led to a 73% objective response rate, including 7 complete responses, in patients with relapsed/refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia.

The FDA has granted a priority review designation to a biologics license application for the anti-CD19 CAR T-cell therapy lisocabtagene maraleucel for the treatment of adult patients with relapsed/refractory large B-cell lymphoma after at least 2 prior therapies.

The FDA has granted a priority review designation to a new drug application for tucatinib for use in combination with trastuzumab and capecitabine for the treatment of patients with unresectable locally advanced or metastatic HER2-positive breast cancer, including patients with brain metastases, following at least 3 prior HER2-directed agents separately or in combination, in the neoadjuvant, adjuvant, or metastatic setting.

The FDA has granted a priority review designation to a new drug application for ripretinib for the treatment of patients with advanced gastrointestinal stromal tumors.

The addition of the off-the-shelf cancer immune primer ilixadencel to sunitinib trended toward a benefit in overall survival compared with sunitinib alone as a first-line treatment for patients with newly diagnosed metastatic renal cell carcinoma.

The United Kingdom’s National Institute for Health and Care Excellence has chosen to not recommend the combination of pembrolizumab and axitinib for use in treatment-naïve adult patients with advanced renal cell carcinoma.

The frontline combination of pembrolizumab and chemotherapy significantly improved progression-free survival compared with chemotherapy alone in patients with metastatic triple-negative breast cancer whose tumors expressed PD-L1.

Patients with high-risk lung cancer who underwent volume CT screening had a significantly lower lung cancer mortality compared with those who were not screened.

The presence of circulating tumor cell was found to be independently associated with relapse in patients with stage III melanoma, suggesting that CTC assessment may be useful in identify patients who are at risk for relapse and could benefit from adjuvant therapy.

Barry Paul, MD, discusses some of the newer data to emerge regarding relapsed/refractory multiple myeloma.

Enzalutamide plus androgen deprivation therapy demonstrated a statistically significant improvement in overall survival compared with placebo/ADT in patients with nonmetastatic castration-resistant prostate cancer.

Pathological fractures in adult patients with high-grade osteosarcoma of the extremities potentially correlates with inferior overall survival.

A supplemental Biologics License Application has been submitted to the FDA for daratumumab for use in combination with carfilzomib and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma.

The FDA has granted a priority review designation to a new drug application for capmatinib for use as treatment for newly diagnosed and previously treated patients with locally advanced or metastatic MET exon14 skipping—mutated non–small cell lung cancer.

The FDA has granted a final approval to pemetrexed for injection, an alternative to standard pemetrexed, for the treatment of patients with locally advanced or metastatic nonsquamous non–small cell lung cancer and for those with malignant pleural mesothelioma.

The FDA has granted a priority review designation to a biologics license application for the investigational CAR T-cell therapy KTE-X19 as a treatment for adult patients with relapsed/refractory mantle cell lymphoma.

Shebli Atrash, MD, discusses some of the latest intriguing research in relapsed/refractory multiple myeloma.

Faculty from NewYork-Presbyterian Hospital/Columbia University Irving Medical Center share their resolutions for the new year and the efforts being made to improve patient outcomes in practice.

William K. Oh, MD, sheds light on how he approaches treatment in patients with metastatic hormone-sensitive prostate cancer.

Peter Voorhees, MD, provides an overview of the many developments made with CAR T-cell therapy in multiple myeloma, as well as the exciting research being done with bispecific antibodies

Jasmeet C. Singh, MD, discusses results from a retrospective analysis looking at the effectiveness of dose dense doxorubicin and cyclophosphamide followed by paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive breast cancer.

Simon Rule, MD, PhD, discusses pooled findings examining ibrutinib in patients with relapsed/refractory mantle cell lymphoma.

Katherine D. Crew, MD, discusses the results of HER2CLIMB and DESTINY-Breast01, as well as other impactful data in HER2-positive breast cancer that emerged from the 2019 San Antonio Breast Cancer Symposium.

The FDA has extended the Prescription Drug User Fee Act deadline for a new drug application for avapritinib as a treatment for adult patients with fourth-line gastrointestinal stromal tumor.

Deepu Madduri, MD, discusses the results of the CARTITUDE-1 trial and the next phase of development with JNJ-4528.

Rita Nanda, MD, discusses ongoing advances with immunotherapy in triple-negative breast cancer, as well as develops in the HER2-negative breast cancer paradigm.

Lee Schwartzberg, MD, FACP, advocates for the increased use of biosimilars in oncology and discusses the benefits of these agents for patients and providers.

Eileen Connolly, MD, PhD, reflects on novel radiation techniques, as well as ongoing research and challenges with radiation therapy in breast cancer.